Investigating Low Survival Rates in Patients With Vulvar/Vaginal Melanomas

Source: Targeted Oncology, May 2021

Annelise Wilhite, MD, of the University of South Alabama Health, discusses a clinical investigation of survival in patients with vulvar/vaginal melanomas.

In a study, patients with vulvar/vaginal melanoma were treated with immunotherapeutic agents like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) had significantly shorter survival compared with patients with cutaneous melanoma treated with the same immunotherapies.

READ THE ORIGINAL FULL ARTICLE